Pneumonia Drug Development Pipeline.pdf

Text-only Preview

Pneumonia Drug Development Pipeline Review, 2017
Summary
This report provides an overview of the pipeline landscape for pneumonia disorders. The report
provides comprehensive information on the therapeutics under development and key players involved
in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and
Ventilator Associated Pneumonia and features dormant and discontinued projects.
Community acquired pneumonia is pneumonia contracted by a person who has had little contact with
the healthcare system, with common symptoms including cough, fever and shortness of breath. Risk
factors include chronic lung disease, cigarette smoking, immune system problems and surgery.
Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-
72 hours after being admitted. Signs and symptoms include malaise, fever, chills, rigor, cough, dyspnea,
and chest pain, but in ventilated patients, pneumonia usually manifests as worsening oxygenation and
increased tracheal secretions.
Finally, ventilator associated pneumonia is pneumonia that occurs in people who are on mechanical
ventilation breathing machines in hospitals. As such the disease typically affects critically ill patients and
increases the risk of mortality. Signs and symptoms include fever or low body temperature, new
purulent sputum and hypoxemia.
The size of these pipelines ranges from 20 products in community acquired pneumonia to 39 in hospital
acquired pneumonia. Across all three of these indications bacterial targets such as DNA gyrase and
ribosomal DNA are the most common targets, closely reflecting the current treatment landscape of
these diseases.
Scope
- Which companies are the most active within the pipeline for pneumonia therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within
each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to
pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of
pneumonia?
Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=41646
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic
development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual
pipeline program in each indication, and a comprehensive picture of recent updates and milestones for
each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the
products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of
action and route of administration
Browse Complete Report @ https://www.reportsworldwide.com/report/pneumonia-drug-
development-pipeline-review-2017
Table of Contents
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Pneumonia Report Coverage 8
2.2 Community Acquired Pneumonia - Overview 8
2.3 Hospital Acquired Pneumonia (HAP) - Overview 8
2.4 Ventilator Associated Pneumonia (VAP) - Overview 8
3 Therapeutics Development 9
3.1 Community Acquired Pneumonia 9
3.2 Hospital Acquired Pneumonia (HAP) 13
3.3 Ventilator Associated Pneumonia (VAP) 19
4 Therapeutics Assessment 24
4.1 Community Acquired Pneumonia 24
4.2 Hospital Acquired Pneumonia (HAP) 30
4.3 Ventilator Associated Pneumonia (VAP) 37
5 Companies Involved in Therapeutics Development 44
5.1 Community Acquired Pneumonia 44
5.2 Hospital Acquired Pneumonia (HAP) 51
5.3 Ventilator Associated Pneumonia (VAP) 64
6 Dormant Projects 75
6.1 Community Acquired Pneumonia 75
6.2 Hospital Acquired Pneumonia (HAP) 76
6.3 Ventilator Associated Pneumonia (VAP) 77
7 Discontinued Products 78
7.1 Community Acquired Pneumonia 78
7.2 Hospital Acquired Pneumonia (HAP) 78
7.3 Ventilator Associated Pneumonia (VAP) 79
8 Product Development Milestones 80
8.1 Community Acquired Pneumonia 80
8.2 Hospital Acquired Pneumonia (HAP) 95
8.3 Ventilator Associated Pneumonia (VAP) 109
9 Appendix 122
9.1 Methodology 122
9.2 Coverage 122
9.3 Secondary Research 122
9.4 Primary Research 122
9.5 Expert Panel Validation 122
9.6 Contact Us 123
9.7 Disclaimer 123
Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=41646
About US:
ReportsWorldwide.com works with leading market research report publishers and consulting
companies worldwide to offer you the best insights into global market trends and technology
developments. Our team constantly works towards bringing on board publishers who cover
both mainstream and niche categories of market research which would suit market
intelligence needs of businesses across the globe.
Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of
market research reports provides in depth coverage of 12 top industry verticals worldwide.
We help you meet your market intelligence needs by mapping it with our database of
market research reports including.
Contact Us:
Reportsworldwide
1503 - A, Oriana
Bandra East,
Mumbai, Maharashtra,
India, 400 051.
Phone: +1 (617) 398-1947